A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group.

This study rapidly assessed the clinical activity of a novel agent in this patient population. Eribulin was well tolerated, but there were no patients who demonstrated objective response, and all patients had progression prior to four months.